MedTrace Logo

Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

NCT00052507 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-07-23

No results posted yet for this study

Summary

RATIONALE: Bortezomib may interfere with the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have metastatic or recurrent colorectal cancer.

Conditions

Interventions

DRUG

bortezomib

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Amit M. Oza, MD · Princess Margaret Hospital, Canada

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2005-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00052507 on ClinicalTrials.gov